Search results for "molecular subtypes"

showing 9 items of 9 documents

Genetic and Epigenetic Characteristics of Inflammatory Bowel Disease-Associated Colorectal Cancer.

2021

doi: 10.1053/j.gastro.2021.04.042 Background & Aims Inflammatory bowel disease (IBD) is a chronic, relapsing inflammatory disorder associated with an elevated risk of colorectal cancer (CRC). IBD-associated CRC (IBD-CRC) may represent a distinct pathway of tumorigenesis compared to sporadic CRC (sCRC). Our aim was to comprehensively characterize IBD-associated tumorigenesis integrating multiple high-throughput approaches, and to compare the results with in-house data sets from sCRCs. Methods Whole-genome sequencing, single nucleotide polymorphism arrays, RNA sequencing, genome-wide methylation analysis, and immunohistochemistry were performed using fresh-frozen and formalin-fixed tissue sam…

0301 basic medicineEpigenomicsMaleColorectal cancerDNA Mutational AnalysisPHENOTYPEmedicine.disease_causeEpigenesis GeneticPATHWAY0302 clinical medicineMUTATIONAL PROCESSESDRIVERSTumor MicroenvironmentFinlandOligonucleotide Array Sequence AnalysisAged 80 and overDNA methylationMETHYLATIONGastroenterologyWnt signaling pathwaytulehdukselliset suolistosairaudetHigh-Throughput Nucleotide SequencingMiddle AgedDNA-metylaatio3. Good healthCell Transformation NeoplasticepigenetiikkaDNA methylationCONSENSUS MOLECULAR SUBTYPES030211 gastroenterology & hepatologyFemaleconsensus molecular subtypeKRASgeneettiset tekijätAdultEpithelial-Mesenchymal TransitionINTESTINAL INFLAMMATIONConsensus Molecular Subtype3122 Cancersepithelial-mesenchymal transitioncolorectal cancersuolistosyövätBiology3121 Internal medicinePolymorphism Single Nucleotide03 medical and health sciencesinflammatory bowel diseaseCOLONAXIN2medicineBiomarkers TumorHumansEpithelial–mesenchymal transitionEpigeneticsneoplasmsSIGNATURESAgedNeoplasm StagingColorectal CancerHepatologyWhole Genome SequencingSequence Analysis RNAGene Expression ProfilingInflammatory Bowel DiseaseDNA Methylationmedicine.diseaseInflammatory Bowel DiseasesEVOLUTIONdigestive system diseases030104 developmental biologyMutationCancer research3111 BiomedicineColitis-Associated NeoplasmsNeoplasm GradingCarcinogenesisTranscriptomeGastroenterology
researchProduct

Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter stud…

2012

Recently, the number of studies on male breast cancer (MBC) has been increasing. However, as MBC is a rare disease there are difficulties to undertake studies to identify specific MBC subgroups. At present, it is still largely unknown whether BRCA-related breast cancer (BC) in men may display specific characteristics as it is for BRCA-related BC in women. To investigate the clinical–pathologic features of MBC in association with BRCA mutations we established a collaborative Italian Multicenter Study on MBC with the aim to recruit a large series of MBCs. A total of 382 MBCs, including 50 BRCA carriers, were collected from ten Italian Investigation Centres covering the whole country. In MBC p…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyMolecular subtypesSettore MED/06 - Oncologia MedicaDNA Mutational AnalysisGenes BRCA2Genes BRCA1Breast Neoplasms MaleYoung Adultclinical-pathologic features; brca2; brca1; male breast cancer; molecular subtypesBreast cancerInternal medicinemedicineCarcinomaHumansYoung adultFamily historyskin and connective tissue diseasesBRCA1; BRCA2; Clinical-pathologic features; Male breast cancer; Molecular subtypesAgedAged 80 and overGynecologybusiness.industryCarcinoma Ductal BreastMiddle Agedmedicine.diseaseBRCA1BRCA2Male breast cancerItalyOncologyMale breast cancerImmunohistochemistryOvarian cancerbusinessClinical-pathologic featureRare disease
researchProduct

Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials

2019

Abstract The Colorectal Cancer Subtyping Consortium identified four gene expression consensus molecular subtypes, CMS1 (immune), CMS2 (canonical), CMS3 (metabolic), and CMS4 (mesenchymal), using multiple microarray or RNA-sequencing datasets of primary tumor samples mainly from early stage colon cancer patients. Consequently, rectal tumors and stage IV tumors (possibly reflective of more aggressive disease) were underrepresented, and no chemo- and/or radiotherapy pretreated samples or metastatic lesions were included. In view of their possible effect on gene expression and consequently subtype classification, sample source and treatments received by the patients before collection must be ca…

Data Analysis0301 basic medicineOncologymedicine.medical_specialtyMicroarrayconsensus molecular subtypesColorectal cancermedicine.medical_treatmentDatasets as TopicReviews03 medical and health sciencesstratification0302 clinical medicineBiasCàncer colorectalInternal medicineBiomarkers TumormedicineHumansRNA-SeqOligonucleotide Array Sequence AnalysisClinical Trials as Topicclinical trialsbusiness.industryPatient SelectionBiochemical markersbiomarkersChemoradiotherapypersonalized medicineHematologyPrognosismedicine.diseaseChemotherapy regimenPrimary tumorColorectal cancerSubtypingRadiation therapyClinical trialTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisMutationgene expressionPersonalized medicineNeoplasm Recurrence LocalColorectal NeoplasmsbusinessMarcadors biomquímics
researchProduct

Precision medicine in breast cancer: reality or utopia?

2017

International audience; Many cancers, including breast cancer, have demonstrated prognosis and support advantages thanks to the discovery of targeted therapies. The advent of these new approaches marked the rise of precision medicine, which leads to improve the diagnosis, prognosis and treatment of cancer. Precision medicine takes into account the molecular and biological specificities of the patient and their tumors that will influence the treatment determined by physicians. This new era of medicine is accessible through molecular genetics platforms, the development of high-speed sequencers and means of analysis of these data. Despite the spectacular results in the treatment of cancers inc…

HER2+0301 basic medicineTumor heterogeneitymedicine.medical_specialtyPathologyMolecular subtypeslcsh:MedicineBreast NeoplasmsReviewCancer VaccinesTumor heterogeneityGeneral Biochemistry Genetics and Molecular BiologyGenetic Heterogeneity03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancer[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyHumansChemotherapyMedicineMedical physicsTriple negativebusiness.industrylcsh:RPrecision medicineCancerGeneral MedicinePrecision medicinemedicine.disease3. Good health030104 developmental biology030220 oncology & carcinogenesisNeoplastic Stem CellsTriple-negativeFemaleImmunotherapyPhase III clinical trialsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyJournal of Translational Medicine
researchProduct

Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemother…

2011

Background Fms-like tyrosine kinase-3 (FLT3) gene mutations are frequent in acute promyelocytic leukemia but their prognostic value is not well established. Design and Methods We evaluated FLT3-internal tandem duplication and FLT3-D835 mutations in patients treated with all-trans retinoic acid and anthracycline-based chemotherapy enrolled in two subsequent trials of the Programa de Estudio y Tratamiento de las Hemopatias Malignas (PETHEMA) and Hemato-Oncologie voor Volwassenen Nederland (HOVON) groups between 1996 and 2005. Results FLT3-internal tandem duplication and FLT3-D835 mutation status was available for 306 (41%) and 213 (29%) patients, respectively. Sixty-eight (22%) and 20 (9%) pa…

MaleAIDA PROTOCOLGene mutationmedicine.disease_causeGastroenterologyLeukemia Promyelocytic AcuteRESIDUAL DISEASEhemic and lymphatic diseasesMOLECULAR SUBTYPESChildanthracyclinesMutationRemission InductionFLT3 mutationshemic and immune systemsHematologyMiddle AgedPrognosisall-trans retinoic acidLeukemiaTreatment Outcomeembryonic structuresFemaleTandem exon duplicationmedicine.drugAcute promyelocytic leukemiaAdultmedicine.medical_specialtyAdolescentAntineoplastic AgentsTretinoinACUTE MYELOID-LEUKEMIABiologyYoung AdultQUALITY-CONTROLTretinoinPOOR-PROGNOSISInternal medicinemedicineCoagulopathyHumansAgedprognostic factorsOriginal Articlesacute promyelocytic leukemiamedicine.diseaseSurvival AnalysisINTERNAL TANDEM DUPLICATIONRISK-ADAPTED TREATMENTPML/RAR-ALPHAfms-Like Tyrosine Kinase 3Fms-Like Tyrosine Kinase 3ImmunologyPETHEMA GROUPMutation
researchProduct

The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications

2021

Tumor infiltrating lymphocytes (TIL) therapy was shown to provide durable objective response in patients with metastatic melanoma. As a fundamental first step to bring TIL therapy to clinical use, identification of patients whose tumors yield optimal numbers of reactive TIL is indispensable. We have previously shown that expansion of tumor reactive TIL from primary bladder tumors and lymph node metastases is feasible. Here, we performed TIL harvesting from additional surgical specimens (additional 31 primary tumors and 10 lymph nodes) to generate a heterogenous cohort of 53 patients with bladder cancer (BC) to evaluate the tumor characteristics that lead to tumor-reactive TIL expansion. Amo…

Malelcsh:Immunologic diseases. AllergyCD3Immunologychemical and pharmacologic phenomenaBacillus Calmette–GuerinLymphocyte ActivationCancer VaccinesImmunotherapy AdoptiveCohort StudiesBasal (phylogenetics)Tumor Necrosis Factor Receptor Superfamily Member 9Lymphocytes Tumor-InfiltratingmedicineImmunology and AllergyHumansadoptive cellular immunotherapyLymph nodeCells CulturedAgedCell ProliferationOriginal Researchmolecular subtypesBladder cancerbiologyTumor-infiltrating lymphocytesbusiness.industryhemic and immune systemsMiddle Agedmedicine.diseaseMycobacterium bovismedicine.anatomical_structureUrinary Bladder NeoplasmsLymphatic Metastasistumor-infiltrating lymphocytesCancer researchbiology.proteinInterleukin-2bladder cancerFemaleLymphAntibodyUrotheliumbusinesslcsh:RC581-607CD8Frontiers in Immunology
researchProduct

Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer

2020

BACKGROUND: Colon cancer (CC) is a heterogeneous disease. Novel prognostic factors beyond pathological staging are required to accurately identify patients at higher risk of relapse. Integrating these new biological factors, such as plasma circulating tumour DNA (ctDNA), CDX2 staining, inflammation-associated cytokines and transcriptomic consensus molecular subtypes (CMS) classification, into a multimodal approach may improve our accuracy in determining risk of recurrence.; METHODS: One hundred and fifty patients consecutively diagnosed with localised CC were prospectively enrolled in our study. ctDNA was tracked to detect minimal residual disease by droplet digital PCR. CDX2 expression was…

OncologyCancer Researchmedicine.medical_specialtyColorectal cancerPathological stagingConsensus molecular subtypesPerineural invasionlcsh:RC254-282Circulating Tumor DNAInternal medicinemedicineBiomarkers TumorHumansDigital polymerase chain reactionCDX2 Transcription Factor1506plasma circulating-tumor DNAStage (cooking)Original Researchbusiness.industryInterleukin-6Plasma circulating-tumor DNA.Multimodal therapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisMinimal residual diseaseColon cancerOncologyColonic NeoplasmsCDX2 homeoprotein; colon cancer; consensus molecular subtypes; interleukin-6; plasma circulating-tumor DNANeoplasm Recurrence LocalbusinessCDX2 homeoproteinImmunostaining
researchProduct

Prognostic Significance of Interferon-γ and Its Signaling Pathway in Early Breast Cancer Depends on the Molecular Subtypes

2020

Interferons are crucial for adaptive immunity and play an important role in the immune landscape of breast cancer. Using microarray-based gene expression analysis, we examined the subtype-specific prognostic significance of interferon-&gamma

OncologyMicroarrayReceptor ErbB-2animal diseasesKaplan-Meier Estimatelcsh:ChemistryMedicinelcsh:QH301-705.5Spectroscopymolecular subtypesHazard ratioGeneral MedicineinterferonMiddle AgedAcquired immune systemProgression-Free SurvivalComputer Science ApplicationsGene Expression Regulation NeoplasticReceptors EstrogenCohortFemaleReceptors ProgesteroneSignal Transductionmedicine.medical_specialtyBreast Neoplasmschemical and pharmacologic phenomenaDisease-Free SurvivalArticleCatalysisInorganic ChemistryInterferon-gammaBreast cancerImmune systembreast cancerInternal medicineBiomarkers TumorHumansPhysical and Theoretical ChemistryMolecular BiologyAgedNeoplasm Stagingbusiness.industryProportional hazards modelOrganic Chemistrybreast cancer ; prognosis ; interferon ; molecular subtypesbiochemical phenomena metabolism and nutritionGene signaturemedicine.diseaselcsh:Biology (General)lcsh:QD1-999bacteriaprognosisbusinessInternational Journal of Molecular Sciences
researchProduct

Krūts vēža molekulāro surogātapakštipu klīniski morfoloģiskais raksturojums sievietēm Latvijā un to saistība ar ķirurģiskās ārstēšanas veida izvēli u…

2015

Elektroniskā versija nesatur pielikumus

Surgical treatmentĶirurģiska ārstēšanaBreast cancerKrūts vēzisMedicīna un farmācijaMolekulārie surogātapakštipiVeselības aprūpeSurrogate molecular subtypesMedicīna
researchProduct